Literature DB >> 10720501

The impact of influenza epidemics on hospitalizations.

L Simonsen1, K Fukuda, L B Schonberger, N J Cox.   

Abstract

The traditional method for assessing the severity of influenza seasons is to estimate the associated increase (i.e., excess) in pneumonia and influenza (P&amp;I) mortality. In this study, excess P&amp;I hospitalizations were estimated from National Hospital Discharge Survey Data from 26 influenza seasons (1970-1995). The average seasonal rate of excess P&amp;I hospitalization was 49 (range, 8-102) /100,000 persons, but average rates were twice as high during A(H3N2) influenza seasons as during A(H1N1)/B seasons. Persons aged <65 years had 57% of all influenza-related hospitalizations; however, the average seasonal risk for influenza-related P&amp;I hospitalizations was much higher in the elderly than in persons aged <65 years. The 26 pairs of excess P&amp;I hospitalization and mortality rates were linearly correlated. During the A(H3N2) influenza seasons after the 1968 pandemic, excess P&amp;I hospitalizations declined among persons aged <65 years but not among the elderly. This suggests that influenza-related hospitalizations will increase disproportionately among younger persons in future pandemics.

Entities:  

Mesh:

Year:  2000        PMID: 10720501     DOI: 10.1086/315320

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  143 in total

1.  The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality.

Authors:  Verena H Menec; Charlyn Black; Leonard MacWilliam; Fred Y Aoki
Journal:  Can J Public Health       Date:  2003 Jan-Feb

Review 2.  Immunity to influenza: the challenges of protecting an aging population.

Authors:  Jacqueline M Katz; Julie Plowden; Mary Renshaw-Hoelscher; Xiuhua Lu; Terrence M Tumpey; Suryaprakash Sambhara
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Influenza update: a review of currently available vaccines.

Authors:  Lisa R Clayville
Journal:  P T       Date:  2011-10

4.  Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus.

Authors:  Jonathan A McCullers; Lee-Ann Van De Velde; Kim J Allison; Kristen C Branum; Richard J Webby; Patricia M Flynn
Journal:  Clin Infect Dis       Date:  2010-06-01       Impact factor: 9.079

Review 5.  The Streptococcus pyogenes proteome: maps, virulence factors and vaccine candidates.

Authors:  Alexander V Dmitriev; Michael S Chaussee
Journal:  Future Microbiol       Date:  2010-10       Impact factor: 3.165

6.  Deletions in the neuraminidase stalk region of H2N2 and H9N2 avian influenza virus subtypes do not affect postinfluenza secondary bacterial pneumonia.

Authors:  Ashok K Chockalingam; Danielle Hickman; Lindomar Pena; Jianqiang Ye; Andrea Ferrero; Jose R Echenique; Hongjun Chen; Troy Sutton; Daniel R Perez
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 7.  The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines.

Authors:  Janet E McElhaney; Xin Zhou; H Keipp Talbot; Ernst Soethout; R Chris Bleackley; David J Granville; Graham Pawelec
Journal:  Vaccine       Date:  2012-01-27       Impact factor: 3.641

8.  Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection.

Authors:  Maria Hedlund; Laura M Aschenbrenner; Kellie Jensen; Jeffrey L Larson; Fang Fang
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

9.  Identifying pediatric age groups for influenza vaccination using a real-time regional surveillance system.

Authors:  John S Brownstein; Ken P Kleinman; Kenneth D Mandl
Journal:  Am J Epidemiol       Date:  2005-08-17       Impact factor: 4.897

Review 10.  Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly?

Authors:  Paul V Targonski; Gregory A Poland
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.